Tarextumab: Development discontinued

OncoMed said it will discontinue all clinical development of tarextumab after reporting data from 145 previously untreated patients with extensive-stage SCLC in

Read the full 229 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE